We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




A MicroRNA Regulates the Activity of the p53 Tumor Suppressor Gene

By LabMedica International staff writers
Posted on 31 Mar 2009
Cancer researchers have discovered a type of microRNA (miRNA) that controls the activity of the p53 tumor-suppressor gene.

In a normal cell p53 is inactivated by its negative regulator, mdm2. More...
When DNA damage or some other forms of stress occur, various pathways lead to the dissociation of the p53 and mdm2 complex. Once activated, p53 will either induce a cell cycle arrest to facilitate repair and survival of the cell or apoptosis to allow the damaged cell to die. While p53 acts to suppress tumor formation, the failure of p53 gene to function correctly has been estimated to lead to more than 50% of cancerous tumors.

Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) and the National University of Singapore worked with a zebrafish model that allowed them to examine which molecules modulated the activity of p53. They reported in the March 17, 2009, online edition of the journal Genes and Development that a microRNA labeled miR-125b was a bona fide negative regulator of p53 in both zebrafish and humans.

Their results showed that a reduction in the amount of miRNA125b in the zebrafish cells caused an increase in the level of p53 and of the number of cells undergoing apoptosis. In contrast, an increase in miRNA125b levels decreased the amount of p53 and the number of apoptotic cells.

"Taking all of this data together, the p53 pathway is a major target of miRNA125b," said contributing author Dr. Harvey Lodish, professor of biology and bioengineering at the Massachusetts Institute of Technology. "Most miRNAs have multiple targets, but there are a few cases that a miRNA has one major target and this is one of them."

Related Links:

Massachusetts Institute of Technology
National University of Singapore




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.